Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?

Journal of Thoracic Disease

Cristina Noberasco¹  Antonio Passaro¹  Gianluca Spitaleri¹  Alessia Pochesci¹  Ester Del Signore¹  Chiara Catania¹  Filippo de Marinis¹ 

[1] Division of Thoracic Oncology, European Institute of Oncology, Milan, ItalyDivision of Thoracic Oncology, European Institute of Oncology, Milan, ItalyDivision of Thoracic Oncology, European Institute of Oncology, Milan, Italy

关键词: Non-small cell lung cancer (NSCLC);    epidermal growth factor receptor (EGFR);    afatinib;    common mutations;    LUX-Lung 7 (LL7);   

DOI  :  10.21037/jtd.2016.02.21

学科分类：呼吸医学

来源: Pioneer Bioscience Publishing Company

【 授权许可】

Unknown